Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
July 23, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
July 10, 2024 07:15 ET
|
Biostem Technologies
BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
June 27, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
June 26, 2024 08:30 ET
|
Biostem Technologies
BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
June 25, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with...
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
June 17, 2024 14:07 ET
|
PRISM MarketView
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
June 17, 2024 10:17 ET
|
PRISM MarketView
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
ViaDerma Provides Highlights of Quarterly Financial Report
June 06, 2024 08:00 ET
|
ViaDerma, Inc.
ViaDerma provides an update on their most recent quarterly financial report
AVITA Medical Achieves Milestone with First Case Using RECELL GO
June 05, 2024 16:25 ET
|
AVITA Medical
Joseph M. Still Burn Center at Doctors Hospital of Augusta treats first patient using AVITA Medical’s FDA-Approved RECELL GO System.
AVITA Medical Announces FDA Approval of RECELL GO
May 30, 2024 09:15 ET
|
AVITA Medical
AVITA Medical receives FDA approval for RECELL GO, its next-generation device used to treat thermal burn wounds and full thickness skin defects.